Sign In

Chas Pulido

General Partner @ Alix Ventures | Creator @ BIOS

Chas Pulido is an experienced investor and entrepreneur currently serving as an Investor at Exthymic since 2024.13 He is also the Founder and General Partner at Alix Ventures, a position he has held since 2020, focusing on early-stage Life Science startups.12

Pulido is known for his work in the biotech and healthcare sectors:

  1. He created BIOS, a content and community platform uniting Life Science industry innovators.2
  2. He has invested in various biotech companies, including Mythic Therapeutics, Strand Therapeutics, ELEGEN, Chemify Limited, Galatea Bio Inc., Zafrens, and Cytosolix.13
  3. Prior to his current roles, he was an Entrepreneur in Residence at Liquid 2 Ventures and co-founded Pareto Life Sciences, which went through Y Combinator.3

Pulido's educational background includes studies at Y Combinator, the University of Notre Dame's Mendoza College of Business, and The Bishop's School.1 He has been recognized as a Business Insider Rising Star VC in 2023 and was named in the Forbes 30 Under 30 list.3

Highlights

Mar 22 · linkedin

Deep Dive: Targeted Protein Degradation

Discover the frontier of medical innovation with Targeted Protein Degradation (TPD), a groundbreaking approach that goes beyond traditional inhibition, completely eliminating elusive proteins by leveraging the body's own cellular machinery. This revolutionary method holds the promise of accessing the vast majority of proteins previously considered "undruggable," including vital transcription factors and scaffolding proteins. With 12 TPD therapeutics currently in clinical trials and the pharmaceutical industry racing to explore this potential, the future of medicine is on the cusp of a paradigm shift. Dive into our latest article to understand how TPD is not just reshaping drug development but also opening new avenues for treating complex diseases with precision and specificity. Join us in exploring how the integration of cutting-edge techniques and the pursuit of small molecule molecular glues could pave the way for highly specific, orally bioavailable therapeutics. Embrace the future of targeted protein degradation and its implications for the pharmaceutical landscape.

Read more about this exciting journey towards drugging the "undruggable."

Mar 20 · linkedin

Ventures ✨ w/ Alexis Borisy & Christoph Lengauer - Co-Founders @ Curie.Bio

Join us on the BIOS Podcast for an enlightening conversation with Alexis Borisy and Christoph Lengauer, the pioneering co-founders of Curie Bio, as we explore the remarkable journeys that led them from the lab to the forefront of biotech entrepreneurship and venture capital. Dive deep into their stories, from Alexis's transition from chemistry scholar to biotech entrepreneur, to Christoph's balancing act between academia and industry, and discover the passion and vision behind Curie Bio. This episode not only sheds light on their individual paths but also delves into the innovative Curie model designed to revolutionize how therapeutics companies are launched. Learn about the strategic diligence process that separates signal from noise, the thoughtful approach to supporting portfolio companies, and the exciting future technologies that have Alexis and Christoph are excited to scale. Whether you're a founder, an investor, or simply fascinated by the intersection of technology and biology, this conversation offers unique insights into navigating the biotech landscape, building successful companies, and the exciting opportunities at the frontier of bio-innovation.

Watch the full episode here: https://buff.ly/4071n3M

#CurieBio #BiotechInnovation #VentureCapital #DrugDiscovery #TechBio #Entrepreneurship #LifeSciences #BiotechStartups #FutureOfHealthcare

Related Questions

What are some of the most innovative startups Chas Pulido has invested in?
How did Chas Pulido's background at Y Combinator influence his investment strategy?
What is the mission behind BIOS and how does it support the Life Science ecosystem?
Can you tell me more about Alix Ventures' approach to supporting early-stage Life Science startups?
What are some key projects or initiatives Chas Pulido has led at Exthymic?
Chas Pulido
Chas Pulido, photo 1
Chas Pulido, photo 2
Add to my network

Location

San Francisco, California, United States